000179994 001__ 179994
000179994 005__ 20180913061439.0
000179994 0247_ $$2doi$$a10.1021/jm300256z
000179994 02470 $$2ISI$$a000305356400008
000179994 037__ $$aARTICLE
000179994 041__ $$aeng
000179994 245__ $$aCytotoxic Effects of Combination of Oxidosqualene Cyclase Inhibitors with Atorvastatin in Human Cancer Cells
000179994 269__ $$a2012
000179994 260__ $$c2012
000179994 336__ $$aJournal Articles
000179994 520__ $$aTen oxidosqualene c-yclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical structure classes were evaluated as potential anticancer agents against human cancer cells from various tissue origins and nontumoral human-brain-derived endothelial cells. Inhibition of cancer cell growth was demonstrated at micromolar concentrations, comparable to the concentrations of statins necessary for antitumor effect. Human glioblastoma cells were among the most sensitive cells. These compounds were also able to decrease the proliferation of angiogenic brain-derived endothelial cells, as a model of tumor-induced neovasculation. Additive effects in human glioblastoma cells were also demonstrated for oxidosqualene cyclase inhibitors in combination with atorvastatin while maintaining selectivity against endothelial cells. Thus, not only statins targeting the 3-hydroxy-3-methylglutaryl coenzyme A reductase but also inhibitors of oxidosqualene cyclase decrease tumor growth, suggesting new therapeutic opportunities of combined anti-cholesterol agents for dual treatment of glioblastoma.
000179994 6531_ $$aHuman Glioblastoma Cells
000179994 6531_ $$aCholesterol-Biosynthesis
000179994 6531_ $$aGlioma-Cells
000179994 6531_ $$aLanosterol Cyclase
000179994 6531_ $$aLipid-Metabolism
000179994 6531_ $$aDown-Regulation
000179994 6531_ $$aRo 48-8071
000179994 6531_ $$aIn-Vivo
000179994 6531_ $$aLovastatin
000179994 6531_ $$aStatins
000179994 700__ $$aStaedler, Davide$$uCHU Vaudois, CH-1011 Lausanne, Switzerland
000179994 700__ $$aChapuis-Bernasconi, Catherine$$uCHU Vaudois, CH-1011 Lausanne, Switzerland
000179994 700__ $$aDehmlow, Henrietta$$uF Hoffmann La Roche Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland
000179994 700__ $$aFischer, Holger$$uF Hoffmann La Roche Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland
000179994 700__ $$aJuillerat-Jeanneret, Lucienne$$uCHU Vaudois, CH-1011 Lausanne, Switzerland
000179994 700__ $$aAebi, Johannes D.$$uF Hoffmann La Roche Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland
000179994 773__ $$j55$$q4990-5002$$tJournal Of Medicinal Chemistry
000179994 909C0 $$0252439$$pISIC$$xU10095
000179994 909CO $$ooai:infoscience.tind.io:179994$$pSB$$particle
000179994 937__ $$aEPFL-ARTICLE-179994
000179994 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000179994 980__ $$aARTICLE